200 related articles for article (PubMed ID: 24105855)
1. Blinded sample size re-estimation for recurrent event data with time trends.
Schneider S; Schmidli H; Friede T
Stat Med; 2013 Dec; 32(30):5448-57. PubMed ID: 24105855
[TBL] [Abstract][Full Text] [Related]
2. Blinded sample size reestimation with count data: methods and applications in multiple sclerosis.
Friede T; Schmidli H
Stat Med; 2010 May; 29(10):1145-56. PubMed ID: 20146203
[TBL] [Abstract][Full Text] [Related]
3. Blinded and unblinded internal pilot study designs for clinical trials with count data.
Schneider S; Schmidli H; Friede T
Biom J; 2013 Jul; 55(4):617-33. PubMed ID: 23703749
[TBL] [Abstract][Full Text] [Related]
4. Blinded continuous monitoring in clinical trials with recurrent event endpoints.
Friede T; Häring DA; Schmidli H
Pharm Stat; 2019 Jan; 18(1):54-64. PubMed ID: 30345693
[TBL] [Abstract][Full Text] [Related]
5. Sample size re-estimation for clinical trials with longitudinal negative binomial counts including time trends.
Asendorf T; Henderson R; Schmidli H; Friede T
Stat Med; 2019 Apr; 38(9):1503-1528. PubMed ID: 30575061
[TBL] [Abstract][Full Text] [Related]
6. Robustness of methods for blinded sample size re-estimation with overdispersed count data.
Schneider S; Schmidli H; Friede T
Stat Med; 2013 Sep; 32(21):3623-35. PubMed ID: 23595966
[TBL] [Abstract][Full Text] [Related]
7. Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design.
Nicholas R; Straube S; Schmidli H; Schneider S; Friede T
Mult Scler; 2011 Oct; 17(10):1211-7. PubMed ID: 21586489
[TBL] [Abstract][Full Text] [Related]
8. Blinded sample size re-estimation for comparing over-dispersed count data incorporating follow-up lengths.
Igeta M; Matsui S
Stat Med; 2022 Dec; 41(29):5622-5644. PubMed ID: 36148560
[TBL] [Abstract][Full Text] [Related]
9. Blinded sample size re-estimation in superiority and noninferiority trials: bias versus variance in variance estimation.
Friede T; Kieser M
Pharm Stat; 2013; 12(3):141-6. PubMed ID: 23509095
[TBL] [Abstract][Full Text] [Related]
10. Blinded sample size re-estimation in three-arm trials with 'gold standard' design.
Mütze T; Friede T
Stat Med; 2017 Oct; 36(23):3636-3653. PubMed ID: 28608469
[TBL] [Abstract][Full Text] [Related]
11. Sample size re-estimation for survival data in clinical trials with an adaptive design.
Togo K; Iwasaki M
Pharm Stat; 2011; 10(4):325-31. PubMed ID: 22328325
[TBL] [Abstract][Full Text] [Related]
12. Sample Size Estimation for Negative Binomial Regression Comparing Rates of Recurrent Events with Unequal Follow-Up Time.
Tang Y
J Biopharm Stat; 2015; 25(5):1100-13. PubMed ID: 25322146
[TBL] [Abstract][Full Text] [Related]
13. Sample size determination and re-estimation for matched pair designs with multiple binary endpoints.
Xu J; Yu M
Biom J; 2013 May; 55(3):430-43. PubMed ID: 23553605
[TBL] [Abstract][Full Text] [Related]
14. Internal pilots for observational studies.
Gurka MJ; Coffey CS; Gurka KK
Biom J; 2010 Oct; 52(5):590-603. PubMed ID: 20857422
[TBL] [Abstract][Full Text] [Related]
15. Sample-size calculation and reestimation for a semiparametric analysis of recurrent event data taking robust standard errors into account.
Ingel K; Jahn-Eimermacher A
Biom J; 2014 Jul; 56(4):631-48. PubMed ID: 24817598
[TBL] [Abstract][Full Text] [Related]
16. Blinded sample size recalculation in multicentre trials with normally distributed outcome.
Jensen K; Kieser M
Biom J; 2010 Jun; 52(3):377-99. PubMed ID: 20394080
[TBL] [Abstract][Full Text] [Related]
17. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
Lachin JM
Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
[TBL] [Abstract][Full Text] [Related]
18. Power analyses for negative binomial models with application to multiple sclerosis clinical trials.
Rettiganti M; Nagaraja HN
J Biopharm Stat; 2012; 22(2):237-59. PubMed ID: 22251172
[TBL] [Abstract][Full Text] [Related]
19. Blinded continuous information monitoring of recurrent event endpoints with time trends in clinical trials.
Mütze T; Salem S; Benda N; Schmidli H; Friede T
Stat Med; 2020 Nov; 39(27):3968-3985. PubMed ID: 32815175
[TBL] [Abstract][Full Text] [Related]
20. Blinded sample size re-estimation in crossover bioequivalence trials.
Golkowski D; Friede T; Kieser M
Pharm Stat; 2014; 13(3):157-62. PubMed ID: 24715672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
